期刊文献+

吡格列酮对2型糖尿病患者血浆内皮素和一氧化氮水平的影响 被引量:2

Effect of Pioglitazone on Endothelin and Plasma of Nitric Oxide in Type 2 Diabetic Mellitus Patients
下载PDF
导出
摘要 目的:探讨吡格列酮对2型糖尿病(T2DM)患者血浆内皮素(ET)、一氧化氮(NO)的影响。方法:70名T2DM患者,随机双盲分为安慰剂组(A组,35例)和吡格列酮组(B组,35例),治疗3个月后,检测两组患者服药前后空腹血糖(FBG)、空腹胰岛素(FINS)、糖基化血红蛋白(HbA1C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、ET和NO,并计算胰岛素敏感指数(ISI)。结果:治疗后吡格列酮组FBG、FINS、HbA1C、TG、ET明显下降(P<0.01),HDL-C、ISI、NO显著升高(P<0.01),ET与FINS呈正相关(r=0.478,P<0.01),与ISI呈负相关(r=-0.306,P<0.01),NO与FINS呈负相关(r=-0.371,P<0.01),与ISI呈正相关(r=0.447,P<0.01);安慰剂组各参数于治疗前后无显著性差异。结论:吡格列酮能够显著降低T2DM患者的ET水平,升高NO水平。 Objective:To study the effects of pioglitazone on endothelin(ET)and nitric oxide(NO)of plasma in type 2 diabetic mellitus(T2DM)patients.Method:T2DM patients(n=70)were divided into placebo group(n=35)and pioglitazone group(n=35)by the rule of random and double-blind.Before and after 3 months treatment,fasting blood glucose(FBG),fasting insulin(FINS),HbA1c,triglyceride(TG),high density lipoprotein-cholesterol(HDL-C),ET and NO were measured.The insulin sensibility index(ISI)was calculated.Results:In pioglitazone group,the levels of FBG,FINS,HbA1C,TG,ET were significantly decreased and the values of HDL-C,ISI and NO were markedly increased(P<0.01)after treatment.The ET value had positive correlation with the FINS(r=0.478,P<0.01)and negative correlation with the ISI(r=-0.306,P<0.01).The NO value had negative correlation with the FINS(r=-0.371,P<0.01)and positive correlation with the ISI(r=0.447,P<0.01).In placebo group,there were no significant differences in the levels of FBG,FINS,HbA1C,ISI,TG,HDL-C,ET,NO before and after treatment.Conclusion:Pioglitazone could significantly reduce ET and increase NO in T2DM patients.
出处 《微循环学杂志》 2008年第4期34-36,共3页 Chinese Journal of Microcirculation
  • 相关文献

参考文献10

二级参考文献34

  • 1郝亚荣,何小俊,周青,韩其蔚,何勇.吡格列酮对2型糖尿病患者颈动脉内膜中膜厚度的影响[J].中国动脉硬化杂志,2005,13(5):627-629. 被引量:5
  • 2Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen aactivator inhibitor-1 and insulin resistance. Diabetes Metab Res Rev,2000,16:192
  • 3Aso Y, Matsumoto S, Fujiwara Y, et al. Impaired fibronolytic compensation for hypercoagulability in obese patients with type 2 diabetes:association with incteased plasminogen activator inhibitor-1. Metabolism,2002,51:471
  • 4Herlihy OM, Barrow BA, Grant PJ, et al. Hyperglycaemic siblings of Type Ⅱ(non-insulin-dependent) diabetia patients have increased PAI-1,central obesity and insulin resistance compared with their paired normoglycaemicsibling. Diabetologia, 2002, 45: 635
  • 5Juban-Vague I, Alessi MC, Mavri A, et al. Plasminogen activator inhibitor-1, inflammation, pbesity, insulin resistance and vascular rish. J Thromb Haemost,2003,1:1 575
  • 6Juban-Vague I, Alessi MC, Morange PE, et al. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med,2000,32(suppl 1):78
  • 7Eriksson P, Nillsson L, Karpe E, et al. Very low density pipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene inplicated in the impaired fibrinolysis of hypertriglyceridemia. Arteriosler Thromb Vasc Biol,1998,18:20
  • 8Sironi L, Mussorri L, Prati L, et al. Plasminogen activator inhibitor type 1 synthesis and mRNA expression in HEPG2 cells and regulated by ALDL. Arteriosler Thromb Vasc Biol,1996,16:89
  • 9Nordt TK, Peter K, Bode C, et al. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrine Metab,2000,85:1 563
  • 10Kern PA,Di Gregorio GB,Lu T,et al.Adiponectin expression from human adipose tissue:relation to obesity,insulin resistance,and tumor necrosis factor-α expression[J].Diabetes,2003 ;52:1779-85.

共引文献2129

同被引文献14

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部